Burning Rock Biotech Limited American Depositary Receipt (6BU0)
XSTU
Closed
Aug 24, 2026
Day's Range
7.6552 wk Range
5.90Overview - 6BU0 - Burning Rock Biotech Limited American Depositary Receipt
Key Statistics
Valuation
Enterprise Value
-435.27M
P/E (Trailing)
‪-1.50‬
PEG Ratio
‪-0.04‬
Price / Book
‪0.15‬
EV / EBITDA
‪17.21‬
Profitability
Gross Margin
‪72.26%‬
Profit Margin
‪74.67%‬
Operating Margin
‪-9.96%‬
Return on Assets
‪-6.74%‬
Return on Equity
‪-10.33%‬
Ownership
Shares Outstanding
105.46M
Price stats
50-Day Avg
‪7.76‬
200-Day Avg
‪14.97‬
Peers - 6BU0 - Burning Rock Biotech Limited American Depositary Receipt
Peer Comparison
Compared with companies in Diagnostics & Research listed on XSTU.
- 6BU0XSTUBurning Rock Biotech Limited American Depositary Receipt+62.30%52-week change-1.34P/E (Trailing)‪74.67%‬Profit Margin
- NL0XSTUGrail, Inc.+57.60%52-week change-6.08P/E (Trailing)‪-236.94%‬Profit Margin
- 8YYXSTUCoro Energy plc+86.30%52-week change0.07P/E (Trailing)‪63.04%‬Profit Margin
- 0MEXSTUTwist Bioscience Corporation+77.96%52-week change-81.58P/E (Trailing)‪50.72%‬Profit Margin
- ILUXSTUIllumina, Inc.+50.05%52-week change29.79P/E (Trailing)‪66.08%‬Profit Margin
- 12VXSTUVeracyte Inc.+49.99%52-week change54.75P/E (Trailing)‪70.10%‬Profit Margin
- 7CCXSTUCheck-Cap Ltd.+48.78%52-week change1.86P/E (Trailing)—Profit Margin
Profile Summary - 6BU0 - Burning Rock Biotech Limited American Depositary Receipt
About
Burning Rock Biotech Limited American Depositary Receipt represents a precision oncology company specializing in next-generation sequencing (NGS)-based diagnostics for cancer therapy selection. The company provides advanced cancer genotyping technologies for both tissue and liquid biopsies, integrating proprietary…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
